JPRN-jRCT2031230442招募中2 期
[M24-311]A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer
Yamagishi Chika0 个研究点目标入组 206 人开始时间: 2023年11月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 206
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Diagnosis of histologically or cytologically confirmed unresectable metastatic colorectal cancer (mCRC).
- •Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
排除标准
- •Harbor the BRAF V600E mutation.
- •dMMR+/MSI-H.
- •Progressed on only one first-line (1L) systemic treatment of combination chemotherapy in the metastatic setting with or without targeted therapy.
- •Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400.
研究者
相似试验
招募中
2 期
[M24-147] Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaJPRN-jRCT2031230144Yamagishi Chika120
进行中（未招募）
1 期
A clinical study to evaluate the safety and efficacy of rivaroxaban in patients with mildCOVID-19 that are at high risk of serious complications such as blood clots that can formin the organs of the body. It is hoped that by intervening early with a drug which thinsthe blood that may prevent progression of mild symptoms to serious complications andsevere disease.EUCTR2020-005395-35-GBBill & Melinda Gates Medical Research Institute600
进行中（未招募）
1 期
A study to assess the schemas of retreatment with Lutathera® in patients with new progression of intestinal well-differentiated neuroendocrine tumor.EUCTR2021-001306-30-FRInstitut Régional du Cancer de Montpellier146
进行中（未招募）
不适用
A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML). - OPTIM IMATINIBChronic Phase Chronic myelogenous leukemia (CP CML)EUCTR2010-019568-35-FRCH VERSAILLES
已完成
2 期
A Phase II, Open, Randomized Study to Assess the Safety and Immunogenicity of Intramuscular KIB-PIA(H5N1 influenza vaccine) in Healthy ChildreJPRN-jRCT2090220015ational Hospital Organization Mie National Hospital175